WCN26-5865 DISPARITY OF NEW DRUG APPROVAL FOR KIDNEY DISEASES BETWEEN JAPAN AND THE UNITED STATES, 2015–2025

Read full text Summarise with VIRAT
Authors: Makoto Miyazawa, Mototsugu TANAKA, Ryohei Terashima, Mio Ezura, Yusuke Tanaka, Yohei Maeda, Haruna Miyazawa, Mutsuhiro Ikuma
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Drug development in nephrology has long lagged behind that in other medical specialties; however, dedicated engagement and collaboration among patients, clinicians, industry, and regulators have accelerated nephrology drug development in recent years. We aimed to analyze the current state of regulatory approvals for nephrology drugs between Japan and the United States (US).

Fields of Study & Subjects

Pharmaceutical Economics and Policy Chronic Kidney Disease and Diabetes Pharmaceutical industry and healthcare

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104837–104837
Publication date
25 March 2026
Language
EN